Diagnostic Medicine Consortium Demonstrates ZetaStorm Platform Integrating Diagnostic Data, Real World Data (RWD), and Clinical Trial Forecasting

Salt Lake City, UT — The Diagnostic Medicine Consortium (DMC)—a joint venture nonprofit of the Project Santa Fe Foundation and the Association for Pathology Informatics (API)—unveiled its emerging technology model at the Project Santa Fe Clinical Lab 2.0 Workshop, held March 2-3, 2026 in Chicago, IL. The demonstrations showed how complex clinical and operational challenges can be addressed through population-scale modeling, neurosymbolic artificial intelligence, and rapid generation of secure clinical software.

At the workshop, DMC introduced ZetaStorm, a neurosymbolic AI system capable of building and verifying auditable, secure software in real time from verbal descriptions. During the demonstration, ZetaStorm generated a clinical trial design tool that extends beyond traditional eligibility criteria to forecast potential clinical trial outcomes—built live in front of the audience.

Because this targeted clinical trial infrastructure draws on biomarker signatures derived from large Real World Data (RWD) datasets, the platform also enables on-demand biomarker validation within the same framework. By integrating diagnostic data, patient stratification, and clinical trial design, the DMC platform creates a critical bridge between the in vitro diagnostics (IVD) sector and pharmaceutical research.

“By demonstrating ZetaStorm’s capacity to rapidly generate targeted clinical trial infrastructure, the Diagnostic Medicine Consortium accelerates the development of diagnostics grounded in Real World Data,” said Vincent Laufer, MD, PhD, Chief Technology Officer of DMC. “In doing so, the DMC creates a critical bridge between the in vitro diagnostics industry and pharmaceutical research, aligning diagnostic capabilities with the emerging demands of targeted clinical trials.”